iRhythm Technologies $IRTC Shares Sold by Segall Bryant & Hamill LLC

Segall Bryant & Hamill LLC decreased its stake in iRhythm Technologies (NASDAQ:IRTC) by 8.7% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 125,298 shares of the company’s stock after selling 11,995 shares during the quarter. Segall Bryant & Hamill LLC owned approximately 0.39% of iRhythm Technologies worth $21,550,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Root Financial Partners LLC acquired a new position in iRhythm Technologies in the third quarter valued at approximately $30,000. Smartleaf Asset Management LLC increased its holdings in shares of iRhythm Technologies by 100.0% during the 3rd quarter. Smartleaf Asset Management LLC now owns 198 shares of the company’s stock valued at $34,000 after purchasing an additional 99 shares in the last quarter. Optiver Holding B.V. acquired a new position in shares of iRhythm Technologies in the 3rd quarter valued at $35,000. Assetmark Inc. boosted its holdings in iRhythm Technologies by 273.9% during the third quarter. Assetmark Inc. now owns 415 shares of the company’s stock worth $71,000 after buying an additional 304 shares in the last quarter. Finally, Lazard Asset Management LLC purchased a new stake in iRhythm Technologies during the second quarter worth $72,000.

iRhythm Technologies Stock Performance

Shares of NASDAQ:IRTC opened at $125.85 on Wednesday. The company has a debt-to-equity ratio of 4.25, a current ratio of 4.63 and a quick ratio of 4.48. iRhythm Technologies has a 1 year low of $92.52 and a 1 year high of $212.00. The firm has a market capitalization of $4.07 billion, a PE ratio of -89.89 and a beta of 1.09. The business’s 50 day moving average price is $159.40 and its 200-day moving average price is $170.14.

iRhythm Technologies (NASDAQ:IRTC) last announced its quarterly earnings data on Thursday, February 19th. The company reported $0.29 earnings per share for the quarter, beating analysts’ consensus estimates of $0.02 by $0.27. iRhythm Technologies had a negative return on equity of 28.15% and a negative net margin of 5.96%.The company had revenue of $208.89 million for the quarter, compared to analyst estimates of $202.61 million. During the same quarter last year, the firm posted ($0.04) EPS. The firm’s revenue for the quarter was up 27.1% on a year-over-year basis. As a group, equities research analysts expect that iRhythm Technologies will post -1.98 earnings per share for the current fiscal year.

More iRhythm Technologies News

Here are the key news stories impacting iRhythm Technologies this week:

• Positive Sentiment: Company guidance: iRhythm updated FY‑2026 revenue guidance to $870.0M–$880.0M, noticeably above the consensus (~$817.3M). Higher top‑line guidance is a positive signal for growth and revenue cadence even though EPS guidance was not specified in the release.
• Neutral Sentiment: Analyst/market note: Coverage is shifting as targets are being reset while management’s guidance holds — a thematic piece that explains why price targets and sentiment may be changing even with stronger revenue guidance. How The iRhythm Holdings (IRTC) Story Is Shifting As Targets Reset And Guidance Holds
• Negative Sentiment: Insider selling: Multiple senior execs sold shares on March 2 — including the CAO, several EVPs and other insiders — totaling ~17,826 shares for roughly $2.29M in proceeds (average price ≈ $128.44). Each reported a mid-single-digit percentage reduction in their holdings; insiders still retain substantial stakes but the clustered selling can be perceived negatively by the market. Representative SEC filing: Insider Form 4

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on IRTC shares. Robert W. Baird cut their price objective on shares of iRhythm Technologies from $220.00 to $200.00 and set an “outperform” rating for the company in a report on Friday, February 20th. Wells Fargo & Company cut their price target on iRhythm Technologies from $225.00 to $200.00 and set an “overweight” rating for the company in a research note on Friday, February 20th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of iRhythm Technologies in a report on Thursday, January 22nd. Canaccord Genuity Group lowered their price target on iRhythm Technologies from $212.00 to $198.00 and set a “buy” rating on the stock in a research report on Friday, February 20th. Finally, Freedom Capital upgraded iRhythm Technologies to a “strong-buy” rating in a research report on Thursday, January 15th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $211.62.

Insider Activity at iRhythm Technologies

In other news, EVP Minang Turakhia sold 4,027 shares of the business’s stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $128.45, for a total transaction of $517,268.15. Following the transaction, the executive vice president directly owned 54,906 shares in the company, valued at $7,052,675.70. The trade was a 6.83% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Patrick Michael Murphy sold 4,357 shares of the company’s stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $128.44, for a total value of $559,613.08. Following the completion of the sale, the insider owned 63,203 shares of the company’s stock, valued at $8,117,793.32. This trade represents a 6.45% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 94,509 shares of company stock worth $12,734,195 in the last 90 days. 0.68% of the stock is owned by insiders.

About iRhythm Technologies

iRhythm Technologies, Inc is a medical technology company that develops and commercializes wearable cardiac monitoring devices and associated data analytics services. Founded in 2006 and headquartered in San Francisco, California, the company’s flagship product is the Zio® patch, a discreet, single-use, continuous ECG recorder designed to monitor heart rhythms for up to 14 days. iRhythm’s digital diagnostics platform combines biosensor technology with proprietary algorithms to detect arrhythmias and streamline data interpretation for physicians.

The Zio service is prescribed by cardiologists and other healthcare providers to aid in the diagnosis of atrial fibrillation, bradycardia, tachycardia and other rhythm disorders.